Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma

Su Min Cho; Abdullah Esmail; Ali Raza; Sunil Dacha; Maen Abdelrahim

doi:10.3390/cancers14112641

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma

Cancers (Basel). 2022 May 26;14(11):2641. doi: 10.3390/cancers14112641.

Authors

Su Min Cho^{1

2

3}, Abdullah Esmail⁴, Ali Raza⁵, Sunil Dacha⁵, Maen Abdelrahim^{2

4

6}

Affiliations

¹ Department of Medicine, Houston Methodist Hospital, Houston, TX 77030, USA.
² Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
³ Department of Medicine, Texas A&M College of Medicine, Bryan, TX 77807, USA.
⁴ Section of GI Oncology, Department of Medical Oncology, Houston Methodist Cancer Center, Houston, TX 77030, USA.
⁵ Department of Gastroenterology, Houston Methodist Hospital, Houston, TX 77030, USA.
⁶ Cockrell Center of Advanced Therapeutics Phase I Program, Houston Methodist Research Institute, Houston, TX 77030, USA.

Abstract

Cholangiocarcinoma (CCA) represents approximately 3% of gastrointestinal malignancies worldwide and constitutes around 10-15% of all primary liver cancers, being only second to hepatocellular carcinoma. Mortality from CCA has been on the rise in recent decades, and in the United States alone there has been a 36% increase in CCA from 1999 to 2014, with over 7000 CCA mortalities since 2013. Targeted therapies, which have been gaining interest due to their greater specificity toward cancer cells, have only recently started gaining FDA approval for the treatment of CCA. In this manuscript, we will go through the timeline of current FDA-approved targeted therapies as well as those that have gained FDA breakthrough therapy designation.

Keywords: CCA; FDA; biliary; cancer; cholangiocarcinoma; targeted therapy.

Publication types

Review

Grants and funding

This research received no external funding.